Podcasts about pharmaceutical

Join us for this episode of the Grammerica Outlaw Roundup, where we delve into a wide array of topics—from mysterious Bigfoot videos and UFO-like claims to discussions on global political dynamics, societal shifts, and cutting-edge technology. Whether you're interested in conspiracy theories, current events, or future predictions, this episode offers a provocative look at the world around us.   Key Topics Covered: Discussions on recent Bigfoot and Sasquatch videos and the authenticity of supernatural claims Analysis of corporate and political figures, including the implications of nepotism and influence peddling Examination of global migration laws and EU policies on borders and deportation Exploration of DARPA's cutting-edge research in genetic technology and information transfer Commentary on societal manipulation, media influence, and the shifting Overton window Insights into recent political spectacles, including the White House fight and nationalistic movements Cultural commentary on feminism, societal debasement, and the influence of mainstream narratives   To gain access to the second half of show and our Plus feed for audio and podcast please clink the link http://www.grimericaoutlawed.ca/support.   For second half of video (when applicable and audio) go to our Substack and Subscribe. https://grimericaoutlawed.substack.com/ or to our Locals  https://grimericaoutlawed.locals.com/ or Patreon https://www.patreon.com/grimericaoutlawed   Support the show directly: https://open.spotify.com/show/2punSyd9Cw76ZtvHxMKenI?si=ImKxfMHgQZ-oshl499O4dQ&nd=1&dlsi=4c25fa9c78674de3 Watch or Listen on Spotify https://www.simulationmaps.com/#products Disaster Maps, Volcano Sim, Asteroid Sim, Shipwreck Map, UFO Map etc https://grimericacbd.com/ CBD / THC Tinctures and Gummies https://grimerica.ca/support-2/ Our Adultbrain Audiobook Podcast and Website: www.adultbrain.ca Check out our next trip/conference/meetup - Contact at the Cabin www.contactatthecabin.com Join the chat / hangout with a bunch of fellow Grimericans  Https://t.me.grimerica grimerica.ca/chats   Discord Chats Darren's books www.acanadianshame.ca Sign up for our newsletter http://www.grimerica.ca/news InstaGRAM https://www.instagram.com/the_grimerica_show_podcast/  Purchase swag, with partial proceeds donated to the show www.grimerica.ca/swag ART - Napolean Duheme's site http://www.lostbreadcomic.com/  MUSIC Tru Northperception, Felix's Site sirfelix.bandcamp.com    Timestamps to the stuff we chatted about: https://x.com/hustlebitch_/status/2065200349858656301?s=43%22%3Ehttps://x.com/hustlebitch_/status/2065200349858656301?s=43%3C/a https://x.com/daniell64334313/status/2065248221224419730?s=43%22%3Ehttps://x.com/daniell64334313/status/2065248221224419730?s=43%3C/a https://x.com/itsolelehmann/status/2065380889337696343?s=43%22%3Ehttps://x.com/itsolelehmann/status/2065380889337696343?s=43%3C/a https://x.com/maximumpain333/status/2067326411292266981?s=43%22%3Ehttps://x.com/maximumpain333/status/2067326411292266981?s=43%3C/a http://x.com/theshadowintelx/status/2066505612775538768?s=43%22%3Ehttps://x.com/theshadowintelx/status/2066505612775538768?s=43%3C/a https://x.com/samahoole/status/2065390399498150051?s=43%22%3Ehttps://x.com/samahoole/status/2065390399498150051?s=43%3C/a https://x.com/valerieanne1970/status/2066853299353969085?s=43%22%3Ehttps://x.com/valerieanne1970/status/2066853299353969085?s=43%3C/a https://x.com/bitcoin_teddy/status/2067007812396343584?s=43%22%3Ehttps://x.com/bitcoin_teddy/status/2067007812396343584?s=43%3C/a https://x.com/forbiddenmerch/status/2067084560463024215?s=43%22%3Ehttps://x.com/forbiddenmerch/status/2067084560463024215?s=43%3C/a https://x.com/deluxe_pepe/status/2067304131652444439?s=20 https://x.com/JasonJournoDC/status/2067314589784527351?s=20 https://x.com/RepLuna/status/2065456539268211065?s=20 https://x.com/DataRepublican/status/2063482589739139124?s=20 https://x.com/DrBitcoinMD/status/2067239149229199815?s=20 https://x.com/MJTruthUltra/status/2065549526744653940?s=20 https://x.com/KanekoaTheGreat/status/2067357923471495403?s=20 https://x.com/Rothmus/status/2065617958752186675?s=20 https://x.com/MJTruthUltra/status/2066568871721701407?s=20 https://x.com/AccolonsMetal/status/2066297235982164425?s=20 https://x.com/irishpatriot91/status/2065499127920636327?s=20 https://x.com/WhiteHouse/status/2066318476403241334?s=20 https://x.com/RichUniverse_/status/2066705488826294667?s=20           Timestamps: 00:00 - Intro and upcoming big event at Serpent Mount 02:00 - Traveling plans and airport customs insights 04:00 - Discussion on Bigfoot clips and potential fakery 05:30 - Examination of preserved Bigfoot body claims and interdimensional theories 07:00 - Analysis of Peter Kane Dog Training videos and their possible hidden meanings 09:00 - Connection between Bigfoot, animatronics, and possible fabricated entities 11:00 - Parody or genuine passion? Deciphering the authenticity of Bigfoot content 12:30 - Trump's "Caesar Maxing" celebrations and political symbolism 15:00 - The spectacle of gladiatorial equivalent events in modern politics 16:30 - Viral fight clips and underdog stories with political overtones 18:00 - Memes and cultural moments from recent events 20:00 - Climate of global migration laws and the EU's strictest policies 22:00 - Scottish World Cup fans and international reactions to celebration 25:00 - Potential for global political shifts with 2024 elections and strategic narratives 28:00 - The influence of deep state narratives around child trafficking and border issues 30:00 - Data centers, secret underground cities, and speculative architectures 33:00 - Skepticism towards corporate-behind-the-scenes projects and technological innovations 36:00 - The role of clones, identity manipulation, and possible AI impersonations in politics 40:00 - Deep dives into global financial conspiracies and wartime narratives 44:00 - Historical medical and societal manipulations over the decades 50:00 - Exposing nepotism, elite influence, and disinformation campaigns 55:00 - EU policies on migration, border enforcement, and sovereignty 60:00 - The history of medical practices gone awry and modern influence operations 65:00 - Pharmaceutical industry propaganda and public health misinformation 70:00 - Political commentary on Hunter Biden, nepotism, and elite corruption 75:00 - Early Joe Rogan interviews with Alex Jones and conspiracy insights 80:00 - The role of alternative medicine, biotech, and potential bioweapons 85:00 - DARPA's mysterious genetic research and implications for reality itself 88:00 - Closing thoughts: the importance of skepticism, awareness, and staying informed  

This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

FOXG1 Research Foundation CEO Nasha Fitter returns to Sounds of Science with extraordinary updates: FDA Fast Track designation, IND clearance, and the first‑ever clinical trial for a FOX G1 gene therapy now within reach. In this episode, hear how science, community, and a mother's determination are rewriting what's possible.  Show Notes Cell and Gene Therapy CDMO Solutions | Charles River Viral Vector Manufacturing Charles River AAV Production for Rare Disease Therapies: From Challenge to Solution | Webcast Rare Disease | Charles River Rare Disease Research for Drug Development | Charles River FOX G1: A Mom's Mission | Podcast 

Scott Ensign, Chief Strategy Officer at Butler/Till, joins Ari Paparo to discuss the advantages of being a 100% employee-owned agency, the rise of agentic AI in media buying, AdCP adoption, and the future of pharmaceutical advertising. Learn how Butler/Till is leveraging AI-powered workflows, healthcare expertise, mobile gaming inventory, and programmatic innovation to drive growth in a rapidly evolving media landscape. Takeaways Butler/Till operates as a 100% employee-owned ESOP, giving employees ownership stakes and allowing the agency to remain independent and agile. The agency is a women-owned and women-led business, with roughly two-thirds of employees being women. Thanks to its status as an independent agency, Butler/Till can operate with agility, making faster decisions and investing strategically without outside shareholder pressure. Butler/Till takes a product-focused approach, building technology and solutions around client needs rather than creating products solely for commercialization. Pharmaceutical advertising is shifting away from broad-reach TV campaigns toward addressable, data-driven digital media channels. Even if pharmaceutical advertising regulations change, opportunities will remain through disease-state education and targeted healthcare professional outreach. Mobile gaming remains an undervalued advertising channel, particularly for reaching healthcare professionals during everyday moments. Butler/Till participated in one of the industry's earliest agentic AI-powered media transactions using AdCP technology. Agentic AI can automate traditionally manual workflows such as RFPs, publisher negotiations, and media planning. The agency views AI primarily as a tool for accelerating work and solving talent shortages rather than replacing employees. Chapters00:00 Introduction to Scott Ensign and Butler/Till00:41 What makes Butler/Till unique as an employee-owned agency01:24 The history behind Butler/Till's ESOP structure02:25 Independent agencies vs. holding companies03:47 Product development and technology investments at Butler/Till04:33 Why Butler/Till hired a Chief Product Officer05:08 How clients approach AI and workflow innovation06:33 The changing landscape of pharmaceutical advertising08:31 Regulatory concerns and the future of pharma marketing10:44 Reaching healthcare professionals in the digital age12:15 Why mobile gaming is an overlooked advertising opportunity14:19 Butler/Till's early agentic AI and AdCP media transaction16:25 How buyer and seller AI agents could negotiate media deals19:28 Why pharma is a strong fit for agentic media buying21:24 Expanding AdCP into audio and offline media channels23:01 AI, efficiency, and the future of agency work23:57 Butler/Till's growth, hiring plans, and closing thoughts Guests: Ari Paparo, Scott Ensign Learn more about your ad choices. Visit megaphone.fm/adchoices

6-11-2026: Wake Up Missouri with Randy Tobler, Stephanie Bell, John Marsh, and Producer Drake

Episode#336-Taped April 22, 2026 We talk about hormone health and hormone therapy. Research has shown that if we use hormone therapy safe and effectively within 10 years of menopause or before age 60 it can offer significant benefits including reduced bone fractures, improved cardiovascular health and reduced cognitive decline. But how does bioidentical hormone replacement therapy and personalized care play a significant role in hormone therapy? Joining us is Nayan Patel, PharmD, he is a clinical pharmacist, and founder of Central Drugs Compounding Pharmacy, a nationally respected facility specializing in bioidentical hormone therapy and personalized care. He will talk about hormone therapy, improving our energy, and our overall health and wellbeing from a pharmaceutical perspective. Dr. Patel will discuss his new book-“The Glutathione Revolution” and how this master antioxidant can help us fight disease, slow aging, and increase energy all the things that we need to have quality of life. Check out Dr. Patel's website Auro Wellness to find out about him and topical glutathione and his patent skincare products. Website: Auro Wellness Go buy Dr. Nayan Patel's Book The Glutatione Revolution It's All About Health & Fitness-Vicki Doe Fitness podcast Ranked on the Top 25 Midwest Fitness Podcasts to Listen to… with additional national recognition on the Top 100 US fitness podcast. Rate This Podcast Give us a 5-star review.  We appreciate you! Take this quick audience survey. Thank you! FREE Metabolic Makeover Masterclass Webinar Replay! Learn how to reset your metabolism, boost energy, and support sustainable weight loss using simple, science-backed strategies. Enroll in the Vicki Doe Fitness Academy to get instant access to the replay and begin your healthy living journey today. Vicki Doe Fitness-STORE Discover the Vicki Doe Fitness-STORE—your destination for stylish apparel, fitness gear, and wellness essentials like yoga mats, water bottles, candles, and premium supplements. Shop now and elevate your health journey! Resources *Note: Some of the resources below may be affiliate links, meaning Vicki Doe Fitness receives a commission (at no extra cost to you) if you use the link to make a purchase. Thank you for your support! Herbs and spices are the keys to delicious, flavorful, and sophisticated meals! FREE DOWNLOAD- Herbs and Spices Cheatsheet Let's get ECO-friendly.  Try ECOLunchbox.com ECOlunchbox specializes in stainless steel bento boxes, artisan fair trade lunch bags, napkins, snack sacks, and other eco-friendly lunchware. They are a certified green business.  ECOlunchbox is a consumer products company started by an eco mom in the San Francisco Bay Area. ECOLunchbox.com Go to our Resources page-   For the most recommended tools, you need to succeed on your healthy living journey!! Listen and share our podcast show- “It's All About Health & Fitness-” Vicki Doe Fitness Subscribe to Apple Podcast Subscribe on Stitcher Or on any of the platforms that you listen to your podcast! Watch & Subscribe on YouTube! Catch our latest health & wellness videos on YouTube at Vicki Haywood Doe – Vicki Doe Fitness YouTube-Vicki Haywood Doe-Vicki Doe Fitness Join us to receive a health wellness message!

REVIEW: Guest Veronique de Rugy critiques the single-payer healthcare model. She argues that European systems "free-ride" on American pharmaceutical and technological innovations, which are driven by the U.S. system's profit motives.

Can custom active‑packaging technology add three years to a drug's shelf life?Badre E. Hammond, Global VP of Aptar Active Material Science, reveals how early‑stage material science can slash development time, meet FDA/EMA requirements, and neutralize nitrosamine risks for pharma, biotech, and med‑tech leaders.Episode sponsor: Aptar Active Material Science is a premier active material science solutions expert that transforms ideas into market opportunities, accelerates and de-risks the product development process.-------------------------Want to stay current with the latest GxP trends? Join our free, enlightening certification webinars at www.qualistery.com.

25-2222_In Re Generic Pharmaceutical

The 3Rs of animal research (Replacement, Reduction, Refinement) are truly a global effort. One of the experts leading this effort is veterinarian Adrian Smith, Secretary of the Norwegian organization Norecopa. Along with Executive Director Global Animal Welfare and Training for Charles River Liz Nunamaker, they share the creation and growth of Norway's National Consensus Platform and Centre for furthering the 3Rs, and how even researchers outside of Norway like Nunamaker benefit from its work.

Want to know what the top earners in pharmaceutical sales actually take home? The numbers you see on job boards dramatically undercount the truth because they leave out quarterly bonuses, RSUs, car allowances, and life-changing equity buyout premiums. Every Monday night, we coach you live to land the job. In this episode of Medical Sales U, Dave Sterrett breaks down the Top 7 Highest-Paying Pharmaceutical Sales Jobs in the country right now. From the incredible work-life balance of dermatology biologics to the multi-millionaire equity upside of oncology biotech startups, we are counting down the real numbers and giving you the honest truth about what it takes to clear the bar and land these elite specialty roles.TIMESTAMPS00:00 - Intro: What Job Boards Get Wrong About Pharma Compensation02:15 - The Total Compensation Formula (Base + Bonuses + RSUs)04:30 - #7: Dermatology Biologics Sales Specialist ($140K - $230K)07:10 - #6: Cardiology & GLP-1 Metabolic Sales Specialist ($155K - $250K)10:05 - #5: Neuroscience & CNS Sales Specialist ($175K - $250K)13:20 - #4: Rare Disease Key Account Specialist ($180K - $300K)16:45 - #3: Biotech Specialty Sales (Gene & Cell Therapy) ($200K - $320K)19:30 - #2: Oncology Sales Specialist - Large Pharma ($200K - $315K)22:15 - #1: Oncology Biotech Startup Sales Specialist ($240K - $350K+ No Ceiling!)24:40 - How to Build Your Record & Earn Clinical CredibilityIf you found this breakdown valuable, please SUBSCRIBE, drop a comment saying “Break in”, and share this with someone mapping out their trajectory in the medical sales industry!Ready to break into medical sales and secure your first $95k+ base offer?Join Medical Sales U: medicalsalesu.com/#MedicalSales #PharmaSales #PharmaceuticalSales #MedicalSalesU #OncologySales #BiotechJobs #HighPayingCareers #SalesCompensation

AABP Executive Director Dr. Fred Gingrich is joined by Dr. Michelle Buckley, Director of Quality Milk Production Services in Warsaw, N.Y. Buckley is also a member of the AABP Committee on Pharmaceutical and Biologic Issues (CPBI) who developed this podcast topic. This episode is sponsored by Boehringer Ingelheim and the Choose360coverage.com mastitis portfolio. The dairy health portfolio that rises to the challenge is Mastitis 360 by Boehringer Ingelheim. It offers powerful solutions for lactation through dry-off. So, manage udder health with the ultimate tools at your disposal. Because you're more than a veterinarian. You're... a hero of the herd. Visit Choose360Coverage.com today. There are two types of compounding that we discuss. This includes compounding from FDA approved products, such as mixing two anesthetic drugs in the same syringe, or compounding from bulk products, such as having a drug made from the raw active pharmaceutical ingredient or from unapproved FDA drugs. Compounding from bulk products for food animals is prohibited in federal statute found at this link. FDA further explains their position on compounding from bulk substances for food animals in GFI# 256 that states that FDA generally does not intend to take enforcement action in cases of compounding from bulk substances to produce antidotes for treating toxicoses in food animals or use as sedatives/anesthetics in free-ranging wildlife species.   Buckley also discusses the differences between compounded products and generic animal drugs and the federal regulations on extralabel drug use. It is important for veterinarians to understand the legal allowances for compounding, extralabel drug use. Veterinarians should use the resources provided by the Food Animal Residue Avoidance Databank (FARAD) for assistance with withdrawal intervals when using extralabel drug use or compounded products.  If you are interested in this topic, consider joining the AABP Committee on Pharmaceutical and Biologic Issues. Find AABP committee resources on this page.  

Listen in as our expert panel unpacks updated definitions of complicated vs. uncomplicated urinary tract infections, navigates antibiotic selection and duration, and shares the latest evidence-based strategies to stop recurrent UTIs in their tracks.Special guests:Dana Bowers, PharmD, BCPS, BCIDPAssociate ProfessorWashington State UniversityAkshith Dass, PharmD, MPH, BCPS, BCIDPAssistant Professor of Pharmacy PracticeNortheast Ohio Medical UniversityPharmacy Clinical Specialist Cleveland Clinic Mercy HospitalYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Craig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in April 2026.

P.M. Edition for May 27. Pharmaceutical companies have been testing a new type of drug to lower levels of lipoprotein(a); high levels have been linked to heart disease and can't be lowered with diet and exercise. WSJ reporter Xavier Martinez walks us through how the new drugs work and what is still needed before they can make their way to patients. Plus, Ford's stock has been surging for the past two weeks, but the reason doesn't have much to do with cars. Journal autos reporter Ryan Felton discusses. And President Trump says he doesn't fear political fallout from the Iran war, while the U.S. blockade throttles the Iranian economy. We hear from WSJ Middle East correspondent Benoit Faucon about what that economic pressure means for both sides as they seek a deal for long-term peace. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

For more information and support, join us at https://thecirsgroup.com Is mold colonization the same as CIRS? Could what looks like a fungal infection actually be something else entirely? In this episode, Barbara is joined by Dr. Lacey Venanzi and Dr. Christian Navarro-Torres to break down the difference between mold/fungal colonization and chronic inflammatory response syndrome (CIRS), explore the surprisingly important role of actinobacteria, and walk through practical, affordable treatment strategies: from pharmaceutical antifungals to botanicals and nasal rinsing. For more information and support, join us at https://thecirsgroup.com TIMESTAMPS 00:00 Intro 01:19 Meet the guests: Dr. Lacey Venanzi & Dr. Christian Navarro-Torres 02:25 What is mold or fungal colonization? 05:01 Is fungal overgrowth a root cause or a downstream effect? 06:08 CIRS vs. fungal colonization: Two distinct diagnoses 07:45 Symptoms of fungal colonization (skin, gut, sinuses, cravings) 10:56 Pharmaceutical antifungals and herbal antifungals 15:30 Risks of using antifungals in CIRS patients 17:25 Why some patients improve on antifungals 19:55 Why timing matters: get out of exposure first 22:25 Actinobacteria: the overlooked player in CIRS 24:19 How actinobacteria mimics fungal infections 26:32 Testing: options, limitations & what to look for 28:15 Key botanical treatments: Horopito, thyme, clove, eucalyptus & tea tree 29:00 Affordable testing options for patients 32:20 Safe steps patients can take (Horopito) 32:49 Dilute the bacteria, lower the burden: cleaning and motility 33:56 Probiotics & prebiotics for fungal/actino burden 35:36 Topical treatment: Horopito Lotion 37:05 Nasal treatment: saline & baby shampoo technique 39:00 Barbara's saline rinse tips & real-world experience 44:03 Why baby shampoo works (surfactants explained) 45:11 Horopito cream for nasal & skin use 47:10 Coherence DX and additional resources Check out Dr. Lacey and Dr. Christian's new company Coherence DX! https://www.coherencedx.com/ YouTube Channel: https://www.youtube.com/@CoherenceDX Dr. Lacey's website: https://www.drlacey.org/ Dr. Christian's website: https://www.cirslab.com/ LINKS MENTIONED IN THE EPISODE: Our Actinos Episode: https://youtu.be/yf9EoTbyAEo?si=nZIZAAlPlBgnObfI Our Actinos Cleaning episode: https://youtu.be/2rCXhUP6dbY?si=TRx356TkQBm1BBJn Our first interview with Dr. Lacey: https://youtu.be/baldT8N7nl4?si=8tHFQCKqrLxiFESq Our latest interview with Dr. Christian: https://youtu.be/Lc_LfUeiYTM?si=6CFLE6w71gtSqStj CSA (comprehensive stool analysis) from ParasiteTesting.com: https://www.parasitetesting.com/CSA?srsltid=AfmBOor_itSEGDFWmeorkB2spnrFXO48-f07lwE7G8V8Hc9NxB4Y92AJ Cheap gut test: https://www.ombrelab.com/products/ombre-gut-health-test?selling_plan=2189295771 More comprehensive gut test: https://www.tinyhealth.com/adult-test SinusKey nose test: https://patients.microgendx.com/products/sinuskey Horopito capsules: https://kolorex.com/collections/gut-care/products/candia-balance-gut-care-60 Dr. Lacey's favorite probiotics: BioGaia: https://a.co/d/0cQZgJhw Florastor: https://a.co/d/09oFxiLs Sun Fiber: https://a.co/d/0hkdbUZh Horopito topical cream (the gentlest option): https://kolorex.com/products/vaginal-care-cream Neti Pot Barbara uses: https://a.co/d/08DKajTT Nasal swabs Barbara uses: https://a.co/d/0fgglU5f Fragrance free Baby Shampoo: https://www.target.com/p/johnson-39-s-sensitive-care-baby-2-in-1-body-wash-38-shampoo-lightly-scented-13-5-fl-oz/-/A-87442350#lnk=sametab Order Jacie's book! The 30 Day Carnivore Bootcamp: https://a.co/d/7MgHrRs The CIRS Group: Support Community: https://thecirsgroup.com Instagram: https://www.instagram.com/thecirsgroup/ Find Jacie for carnivore, lifestyle and limbic resources: Jacie's book on the Carnivore diet!  https://a.co/d/8ZKCqz0 Instagram: https://www.instagram.com/ladycarnivory YouTube: https://www.youtube.com/@LadyCarnivory Blog: https://www.ladycarnivory.com/ Find Barbara for business/finance tips and coaching: Website: https://www.actlikebarbara.com/ Instagram: https://www.instagram.com/actlikebarbara/ YouTube: https://www.youtube.com/@actlikebarbara Jacie is a Shoemaker certified Proficiency Partner, NASM certified nutrition coach, author, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a business and fitness coach, CIRS and ADHD advocate, writer, speaker, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment.

I n early 2026, pharmaceutical manufacturers announced list price increases on at least 350 brand-name medications, continuing a pattern that affects treatments for cancer, COVID-19, migraines, and other conditions despite policy efforts to enhance affordability. This episode examines the scope of these hikes, notable examples such as Pfizer's adjustments to Ibrance and Comirnaty, and the broader context of Medicare negotiations that provide relief for select drugs. Listeners will gain insights into the economic drivers, patient impacts, and potential long-term consequences for healthcare access and innovation.100

What happens when a doctor starts questioning the very system he was trained in? In this eye-opening and deeply important conversation, Darin Olien sits down with physician and metabolic health expert Dr. Dan Reardon to unpack the exploding GLP-1 weight loss drug phenomenon, the collapse of foundational health principles, and the dangerous trend of masking chronic disease instead of addressing root causes. Together, they dive into protein myths, obesity culture, pharmaceutical incentives, body positivity, metabolic dysfunction, chronic disease, and the growing "Wild West" of weight-loss injections like semaglutide and Mounjaro. But this conversation goes much deeper than weight loss. Dr. Reardon reveals his revolutionary focus on "deprescribing" medications—helping patients safely come off statins, blood pressure medications, psychiatric drugs, and GLP-1 injections by restoring the body's innate healing systems. This episode is a powerful exploration of personal sovereignty, metabolic health, medical integrity, and why the human body may be far more intelligent than modern medicine gives it credit for. What You'll Learn Why the current protein obsession may be misunderstood How the body recycles amino acids and adapts to exercise The hidden problems with ultra-high protein consumption Why GLP-1 drugs like semaglutide and Mounjaro are raising serious concerns The cultural shift from body positivity to weight-loss injections The pharmaceutical industry's incentives around obesity medications Why most people using GLP-1 drugs are not changing their lifestyle habits The side effects associated with semaglutide and related drugs How chronic disease is often treated symptomatically instead of at the root cause Why Dr. Reardon focuses on "deprescribing" medications The importance of metabolic health and foundational lifestyle medicine How modern medicine often ignores why symptoms are happening in the first place Chapters 00:00:03 – Welcome to SuperLife 00:00:32 – Sponsor: Manna Vitality and frequency-based wellness 00:02:00 – Introducing Dr. Dan Reardon and the focus of today's conversation 00:02:39 – Protein myths and amino acid recycling in the body 00:03:00 – GLP-1 injections, semaglutide, and the weight-loss drug explosion 00:03:38 – Pancreatitis, gallbladder disease, bone loss, and hidden side effects 00:04:00 – Dr. Reardon's mission to "deprescribe" medications 00:04:22 – Why symptoms and inflammation often exist for a reason 00:04:45 – Darin and Dan reconnect after more than a decade 00:05:39 – Their original conversation about protein and muscle breakdown 00:06:11 – How the body recycles amino acids instead of wasting them 00:06:59 – Questioning mainstream protein requirements 00:08:00 – Plants as the original source of amino acids 00:08:27 – Why protein discussions remain controversial 00:08:46 – Appetite regulation, exercise, and protein utilization 00:09:27 – The flipped food pyramid and rising protein recommendations 00:10:11 – Darin critiques the meat-heavy food system 00:11:05 – Subsidized meat production and processed food systems 00:11:54 – Environmental impacts of increased protein consumption 00:12:15 – Longevity science and the dangers of excess protein intake 00:13:17 – Cancer risk, mortality, and overconsumption of protein 00:13:47 – The absurdity of protein-fortified processed foods 00:14:17 – Observing GLP-1 users still eating ultra-processed foods 00:15:04 – Society abandoning foundational health principles 00:15:50 – The body's natural GLP-1 mechanisms through movement and nutrition 00:17:08 – How semaglutide was originally developed 00:18:00 – Why injected GLP-1 drugs are not "natural" GLP-1 00:19:13 – Softening pharmaceutical language to increase acceptance 00:20:00 – The "Wild West" rollout of GLP-1 medications in the UK 00:20:33 – Government incentives pushing doctors to prescribe GLP-1 drugs 00:21:24 – Weight regain and muscle loss after stopping the injections 00:22:04 – The lack of transparency around side effects 00:22:15 – Pancreatitis, gallbladder disease, and long-term bone density concerns 00:22:58 – "Yo-yo injectors" using semaglutide for weddings and vacations 00:23:29 – Pharmaceutical culture prioritizing profit over long-term health 00:24:26 – Emotional vulnerability and the appeal of "miracle" weight-loss drugs 00:25:03 – Trusting authority figures without informed consent 00:25:34 – Why behavioral support often fails after GLP-1 treatment 00:26:07 – Sponsor: Tru Niagen and cellular NAD+ support 00:28:33 – Most people simply eat less junk food—not healthier food 00:29:00 – Why physicians struggle to keep up with rapidly changing medicine 00:30:10 – The pressure doctors face from patients demanding GLP-1 prescriptions 00:31:11 – Traditional uses for GLP-1 medications in diabetes care 00:31:36 – Why many experienced physicians refuse to prescribe these drugs 00:31:55 – Online pharmacies and supermarkets selling injections directly 00:32:17 – Doctors are not trained in emotional eating or lifestyle coaching 00:33:04 – Younger doctors inheriting pharmaceutical-driven systems 00:34:00 – Acknowledging cases where GLP-1 drugs may genuinely help 00:34:26 – The widespread abuse of semaglutide medications 00:35:18 – The changing culture inside medical schools and training systems 00:36:12 – Circumventing medical oversight through online prescriptions 00:37:17 – The disappearance of the body positivity movement 00:38:04 – Society normalizing obesity before introducing weight-loss injections 00:39:06 – Darin reflects on self-worth, consciousness, and the human body 00:40:15 – Loving people without confusing identity with physical health struggles 00:41:17 – Supporting people biologically rather than shaming them emotionally 00:42:30 – Manufactured health crises and systemic manipulation 00:43:17 – Darin and Dan discuss Fatal Conveniences and societal deception 00:44:11 – Questioning systems while helping people reclaim health sovereignty 00:45:12 – Why foundational health habits still matter most 00:45:51 – The psychological value of struggle, resilience, and achievement 00:46:50 – Human resilience and ancestral survival 00:47:19 – Resistance training and building emotional strength 00:47:44 – Dr. Reardon's current focus on deprescribing medications 00:48:20 – Helping patients improve metabolic health naturally 00:49:00 – Interpreting modern bloodwork and health testing 00:49:46 – Why patients don't want to return to medications once they heal 00:50:13 – Helping the body "come back online" naturally 00:50:42 – The body's intelligence and adaptive inflammatory responses 00:51:44 – Suppressing symptoms without resolving root causes 00:52:17 – High blood pressure as a signal—not just a diagnosis 00:53:04 – Investigating why symptoms happen instead of masking them 00:53:46 – Medicine as detective work 00:54:14 – Building a medical practice aligned with integrity 00:55:10 – Why healthcare systems need course correction 00:56:23 – Final reflections on truth, integrity, and helping people thrive Join the Superlife Community Get Darin's deeper wellness breakdowns — beyond social media restrictions: Weekly voice notes Ingredient deep dives Wellness challenges Energy + consciousness tools Community accountability Extended episodes Join for $7.49/month → https://patreon.com/darinolien     Find More from Dr. Dan Reardon Website: https://www.drdanreardon.com/  Instagram: @drdanreardon Get Your GLP1 Timeline Tool: Website Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences Key Takeaway "The human body is not broken: it is adaptive, intelligent, and constantly responding to the environment it's placed in. Modern medicine often suppresses symptoms without asking why they exist in the first place. Real healing begins when we stop chasing shortcuts, start addressing root causes, and create the conditions for the body to do what it was designed to do all along: heal, regulate, and thrive."

In this episode of Talking Sleep, host Dr. Seema Khosla welcomes Dr. Daniel Buysse and Dr. Todd Arnedt, both members of the AASM clinical practice guideline committee, to discuss the newly released guidelines on combination treatment for chronic insomnia disorder in adults. Unlike previous guidelines, this new guidance specifically addresses what happens in real-world clinical practice: patients often request both cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, or arrive seeking medications while clinicians advocate for behavioral interventions. The guidelines provide evidence-based recommendations for navigating these combination treatment scenarios, incorporating patient preferences in ways previous guidelines did not. The conversation explores the guideline development process, including how committee members were selected and how diverse professional backgrounds enriched the discussion. Dr. Buysse and Dr. Arnedt explain why patient preference wasn't adequately reflected in original practice guidelines and how this updated version addresses that gap. The first recommendation receives detailed examination: In adults with chronic insomnia, the AASM suggests combination treatment with CBT-I plus medication over medication alone (conditional recommendation, low certainty of evidence). The experts clarify which medications were examined, including whether dual orexin receptor antagonists (DORAs) were included, and explain why evidence certainty is low despite numerous studies. Pharmaceutical sponsorship creates methodological differences—PSG outcomes, fixed time in bed requirements—that complicate interpretation. The high placebo response in insomnia trials adds another layer of complexity. Critical implementation questions arise: What does "combination therapy" actually mean? Should both treatments start simultaneously, or should one precede the other? Can patients start medications while awaiting CBT-I appointments given typical access delays? The second recommendation appears paradoxical: The AASM suggests against combination treatment over CBT-I alone, yet recommends combination over medication alone. Dr. Buysse and Dr. Arnedt explain this nuanced position—CBT-I alone remains superior, but for patients who prioritize rapid total sleep time improvement over daytime symptom reduction, combination therapy may be reasonable. The conversation addresses whether treatment order matters and whether clinical (not just insurance-driven) logic suggests a medication hierarchy—zolpidem before eszopiclone, the role of trazodone, when to consider ramelteon. A crucial question emerges: What about patients who refuse or cannot access CBT-I? How do these guidelines apply when the preferred behavioral treatment is unavailable or unwanted? Throughout, the experts emphasize that guidelines inform but don't dictate clinical decisions. Patient preferences, values, and individual circumstances must shape treatment plans. The guidelines provide evidence-based frameworks while acknowledging the complexity of real-world insomnia management. Whether you're treating chronic insomnia, navigating patient requests for medications, addressing CBT-I access barriers, or seeking evidence-based approaches to combination therapy, this episode provides essential guidance. Join us for this important conversation about balancing behavioral and pharmacological approaches to chronic insomnia in clinical practice.

As municipal water utilities increasingly shift from free chlorine to chloramine disinfection strategies, pharmaceutical manufacturers are facing new challenges in maintaining consistent, high-purity water systems. While chloramines provide utilities with longer-lasting residual disinfection and reduced formation of regulated byproducts, they also introduce operational risks inside pharmaceutical facilities. As a result, manufacturers are reassessing traditional chloramine removal approaches and exploring more proactive treatment strategies that improve resiliency, monitoring, and long-term operational efficiency.   In this episode of Off Script, sponsored by Trojan Technologies, we spoke with Wayne Lem, global applications manager at Trojan Technologies, about the evolving role of UV technology in pharmaceutical water treatment systems. The conversation explores how chloramine shifts at the municipal level are impacting pharmaceutical manufacturing operations, the limitations of traditional approaches like catalytic carbon and reducing chemicals, and how UV-based chloramine destruction can help facilities improve process reliability while reducing maintenance and chemical dependency. Lem also discusses the operational and economic considerations behind UV adoption, the importance of continuous monitoring and validation in regulated environments, and why hybrid, multi-barrier treatment strategies are becoming increasingly important as manufacturers modernize water infrastructure.

European countries need to become more self-sufficient in medication production in troubled times, but is it possible at all? Six years after the Covid 19 pandemic, the EU will soon adopt its Critical medicines act to tackle medicines shortages in Europe. Production: By Europod in co-production with the Sphera Network.This episode is based on an article written by Paweł Jędral for Krytyka Polityczna and is co-written with Hélène Pillon from Médianes. Hosted on Acast. See acast.com/privacy for more information.

Applied Biopharm Consulting Ltd has announced a new research collaboration with the Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) at the South East Technological University (SETU) in Waterford, Ireland, to experimentally validate aspects of its artificial intelligence (AI)-driven biomolecular research programme. The collaboration is supported through the Enterprise Ireland Innovation Voucher scheme, enabling the company to access specialised laboratory expertise within the university. With strong research activity across pharmaceutical science, biotechnology and applied life sciences and supported by the Enterprise Ireland Technology Gateway programme PMBRC has developed extensive capabilities in industry-focused research and collaboration with emerging technology companies. Through this collaboration, cell-based studies will be undertaken at SETU to generate experimental data supporting the continued development of Applied Biopharm Consulting's computational viral vector engineering platform. These studies will provide experimental validation to complement the company's computational research activities. Building on its 2024 feasibility study grant and the subsequent Intellectual Property (IP) Start Grant awarded in 2026 under Enterprise Ireland's IP Strategy initiative, Applied Biopharm Consulting continues to expand its internal research and development programme focused on next-generation viral vector engineering. The Innovation Voucher collaboration represents the next step in translating computational research into experimentally validated technologies while supporting the company's ongoing intellectual property strategy. Applied Biopharm Consulting's research programme integrates artificial intelligence, structural bioinformatics and molecular simulation techniques to analyse large datasets of protein structures and explore novel biomolecular interactions. These computational approaches are being applied to explore new strategies for viral vector design relevant to advanced biologics and gene therapy development. Dr. Anthony Newcombe, Managing Director of Applied Biopharm Consulting Ltd, commented: "Establishing a research collaboration with South East Technological University represents an important step in advancing our viral vector engineering programme from computational design toward experimental validation. The Innovation Voucher scheme enables us to access specialised academic expertise and laboratory capabilities that complement our computational research platform." Dr Niall O'Reilly, Centre Director of the PMBRC added: "We are pleased to collaborate with Applied Biopharm Consulting on this research initiative. Partnerships between academia and industry provide valuable opportunities to translate innovative ideas into experimentally validated technologies, and this project highlights how academic research capabilities can support emerging biotechnology innovation. This collaboration also fits well into our current research portfolio in areas such as gene therapy and biomedical science" The collaboration represents the next stage in Applied Biopharm Consulting's internal research and development (R&D) programme, which combines computational biologics research with experimental validation and intellectual property development. Alongside its research activities, Applied Biopharm Consulting continues to support global biopharmaceutical companies in GMP compliance, Regulatory CMC, Manufacturing Science & Technology (MSAT), Quality Assurance and technology transfer. By integrating extensive regulatory and manufacturing expertise with next-generation biologics engineering capabilities, the company is positioning itself at the intersection of advanced therapy development and biologics innovation. See more stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episod...

The successful conclusion to the Artemis II mission on April 10, 2026, ushered in a new era of enthusiasm for manned space flight. For NASA, the next steps in this incredible journey will include mankind's establishing permanent habitation on the moon and Mars. But a lot of work has to be done before those dreams can be fully realized. For example, what supporting infrastructure will be needed to underpin these future colonies, and how do we build it in airless, waterless environments? Our guests today include Dr. Nancy Currie-Gregg, former NASA astronaut and current director for the newly minted Texas A&M University Space Institute, and TTI Agency Director Greg Winfree. TTI is teaming with the A&M Space Institute to help Texas and the United States position themselves to advantage in the growing space economy. | Learn More about the Texas A&M Space Institute

What does it really take to land a successful biotech partnership—and what makes a deal fall apart? In this episode, host Elaine Hamm, PhD, sits down with Renee Williams, PhD, MBA, Founder and Managing Partner of Williams Biotech Consulting and Independent Board Director for AGS Therapeutics. With experience across major pharma companies like Eli Lilly and Janssen, Renee shares hard-earned insights from the front lines of dealmaking. From communication missteps to finding the right partner, she explains how to navigate biotech partnerships with clarity, confidence, and strategy. In this episode, you'll learn: Why overcommunication is key to every stage of the deal process. How to identify (and avoid) red flags in strategic partnerships. What scientists need to know to transition into biotech business roles. Whether you're negotiating a licensing deal or dreaming of your first exit, this episode is packed with advice you won't want to miss. Links: Connect with Renee Williams, PhD, MBA, and check out Williams Biotech Consulting and AGS Therapeutics. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about Eli Lilly and Janssen Pharmaceutical. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== John sits down with Barry Patel, co-founder of Galt Pharmaceuticals, to talk about a franchise model built specifically for healthcare professionals looking to build equity outside of clinical practice. Galt distributes FDA-approved products with a focus on non-opioid pain management directly through independent pharmacies, bypassing the traditional wholesale channel entirely. The result is a leaner cost structure, better patient access, and a business opportunity that doesn't require leaving healthcare to pursue. Barry walks through how the franchise system works, what it takes to qualify as a franchisee, and why independent pharmacies are central to the model. With 500 territories across the U.S. and 450 still available, the opportunity is early-stage enough to be worth understanding now. You'll find links mentioned in the episode at nonclinicalphysicians.com/pharmaceutical-franchise/

Santa Virus because it's as fake as the Easter Bunny. David Lee Corbo (The Raven) and Top Lobsta break down the latest “outbreak” footage that looks EXACTLY like the staged China COVID hazmat videos, the same guy pushing vaccines on the ship who was pushing them in 2020, and why “Hanta” literally means “bullshit/lie” in Hebrew.We go full conspiracy bukkake on:• Economist Magazine 250th Birthday cover — cannons shooting the American cake, BRICS swords, melting ice, robotic dogs, Persian ships, soccer ball kickoff, dollar bills blowing away, and pharmaceutical pills everywhere• UFO/UAP “disclosure” slop — fake AI-generated CIA humanoid N-7 document, Japan confirming U.S. footage, Tim Burchett's “holy f*ck moment,” Anna Paulina Luna threatening the CIA over MKUltra & JFK files, Tulsi Gabbard office raid• NASA nuclear engineer Joshua found dead — Tesla crash, FBI investigation, two similar scientist deaths in weeks• Pastor scandals exploding right as disclosure hits — Perry Stone (12 women sexual harassment + suicide threat), Joseph Z “prophet,” and the February meeting domino effect• Orthodox Church beef — Peter the Rock, “upon this rock” debate, kissing dead bones, and why it matters during demonic deception rollout• MKUltra → Puharich → The Nine → UFO screen memories connection• King Charles announcing Digital ID while we're distracted by hantavirus + aliens  Plus live audience chaos, Nancy popping in, Top Lobster's latest merch, and zero filter as always.If you're tired of the slop, this is the episode that connects EVERY dot.Get early access, ad-free, private Telegram/Discord + merch discounts: patreon.com/nephilimdeathsquad Tickets for BroGrove / Bohemian Grove Day (Aug 8) → TopLobsta.comShirts & gear: TopLobsta.com0:00 – Intro + “Regular-sized dude, regular-sized hands, regular-sized dick” banter  2:15 – Welcome to Neph to America, cultural commentary for the end of days  3:40 – Patreon plug, overtime workers, Brogrove tickets (Aug 8 General Admission)  7:25 – Hantavirus renamed “Santa Virus” – son's story + controlled demolition analogy  11:10 – Economist Magazine 250th Birthday cover deep dive begins  14:50 – Cargo ship shooting cannons at America's birthday cake  17:30 – Crossed swords (Two of Swords tarot), downward graph, discontinued pennies  20:15 – Putin & Xi Jinping, BRICS economic war symbolism, cracked dollar sign  23:40 – Flying dollar bills + leaves (Leave the World Behind reference), gavel  26:10 – Boston Dynamics robot dogs + automatons, Persian ships & Polynesian hats  29:45 – Soccer ball kickoff prophecy + World Cup disclosure theory  33:20 – Pharmaceutical pills, syringes, melting ice cubes, wine spill – Q1/Q2 breakdown  37:05 – UFO Disclosure slop: fake AI-generated CIA “N-7 Non-Human Entity” document  42:30 – Pastor scandals explode same week as disclosure – Perry Stone (12 women) & Joseph Z  48:15 – Orthodox Church debate: “Upon this rock” – Peter the Rock vs revelation principle  54:40 – Kissing dead bones, institutional traps, and why you should still go to church  1:01:10 – Japan confirms U.S. UAP footage + Chief Cabinet Secretary Kihara  1:05:50 – Tim Burchett “holy f*ck moment” clip + slow-roll disclosure strategy  1:10:25 – Anna Paulina Luna threatens CIA over MKUltra + JFK files raid on Tulsi Gabbard's office  1:16:40 – MKUltra → Puharich → The Nine connection & screen-memory abductions  1:22:15 – NASA nuclear engineer Joshua found dead – Tesla crash, FBI investigation  1:27:50 – Hantavirus cruise ship psyop footage – identical to 2020 China hazmat videos  1:33:10 – Same COVID vaccine guy now on Hantavirus ship reading from script (same shirt + hat)  1:38:45 – “Hanta” means “bullshit/scam” in Hebrew + gematria Easter eggs  1:43:20 – King Charles announces Digital ID while we're distracted by virus + aliens  1:47:30 – Mom's viral clips (Trump phone, knife-gun, reptile statue, tall whites AI slop)  1:53:10 – Gematria guy meltdown, Cole Allen White House, “nobody ever dies” flat-earther comedy  1:58:40 – Final plugs: Brogrove tickets, TopLobster.com merch, Patreon, no new friends policy  2:01:50 – Outro + “They bred with turtles of men” sign-offBecome a supporter of this podcast: https://www.spreaker.com/podcast/nephilim-death-squad--6389018/support.☠️ Nephilim Death Squad — New episodes 5x/week.Join our Patreon for early access, bonus shows & the private Telegram hive.Subscribe on YouTube & Rumble, follow @NephilimDSquad on X/Instagram, grab merch at toplobsta.com. Questions/bookings: chroniclesnds@gmail.com — Stay dangerous.

Think the real money in medical sales is only in the Operating Room? Think again.Discover how specialty Pharma and Oncology reps are quietly earning $200K - $300K+ without ever stepping into a scrub suit. In this episode, Dave Sterrett, founder of Medical Sales U and former #1 national rep at Sanofi and Virtuox, breaks down the exact numbers behind the most misunderstood — and lucrative — side of the industry: Specialty Pharma and Oncology Diagnostics.Stop listening to the "device youtuber" that says Pharma is just dropping off samples. We're diving into the high-level clinical selling required to dominate oncology and precision medicine. TOPICSThe Income Reality: Why the "floor" for our members starts at a $95,000 base salary.The Career Ladder: A step-by-step breakdown from entry-level ($110k) to Oncology ($230k+ base).Beyond the Salary: The "hidden" wealth in RSUs, ESPPs, and expense accounts that add $50k+ in value.The Interview Secret: Why smart people fail the "Clinical Conversation" and how to fix it.Work-Life Balance: Why veteran Device reps are leaving the OR for the flexibility of Pharma. CHAPTERS0:00 - The Case for Pharma & Diagnostics2:15 - My Journey: Turning a Territory Around5:45 - Debunking the "Pharma is Easy" Myth10:30 - The Salary Floor: $95k - $125k Base15:10 - The Oncology Tier: $150k - $230k Base20:45 - The Truth About OR Burnout28:30 - How to Master the Clinical Conversation35:00 - Building Generational Wealth with Equity Ready to break into medical sales and secure your first $95k+ base offer?Join Medical Sales U: medicalsalesu.com/Every Monday night, we coach you live to land the job.

The Nurses Report with Ashley, Nicole, & David – Pharmaceutical bribery erodes patient safety as companies manipulate science, influence regulators, and hide harms behind settlements and sealed documents. Nurses, families, and honest clinicians confront the human cost of corruption, demanding transparency, retractions, stronger oversight, and accountability that puts patients before profits and restores public trust in medicine...

The Nurses Report with Ashley, Nicole, & David – Pharmaceutical bribery erodes patient safety as companies manipulate science, influence regulators, and hide harms behind settlements and sealed documents. Nurses, families, and honest clinicians confront the human cost of corruption, demanding transparency, retractions, stronger oversight, and accountability that puts patients before profits and restores public trust in medicine...

25 years ago, the FDA approved a pill that would change the way scientists treat cancer … for good. The pill was called Gleevec; it was designed specifically to treat CML, chronic myeloid leukemia, and it was one of the first targeted cancer therapies available. A quarter century after approval, it's still being prescribed, as are second, third and fourth-generation drugs that followed in its footsteps. What made it so special – and so effective? Pharmaceutical correspondent Sydney Lupkin walks us through the history of the drug, and why it's continued to change lives for decades.If you liked this episode, check out our other episodes with Sydney on accelerated drug approvals and the development of GLP-1 pills.Interested in more stories about medicine and medical treatment? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

Medical cannabis producers must meet strict EU GMP standards. From cleanroom design to quality systems, here's why facility design and validation are critical for compliance and success. For more information, please visit: https://hempirelabs.com Hempire Labs S.L. City: Sotogrande Address: C.C., Mar y Sol Local 3.9 Website: https://hempirelabs.com

Medical cannabis producers must meet strict EU GMP standards. From cleanroom design to quality systems, here's why facility design and validation are critical for compliance and success. For more information, please visit: https://hempirelabs.com Hempire Labs S.L. City: Sotogrande Address: C.C., Mar y Sol Local 3.9 Website: https://hempirelabs.com

Medical cannabis producers must meet strict EU GMP standards. From cleanroom design to quality systems, here's why facility design and validation are critical for compliance and success. For more information, please visit: https://hempirelabs.com Hempire Labs S.L. City: Sotogrande Address: C.C., Mar y Sol Local 3.9 Website: https://hempirelabs.com

In this episode, guest Antonio Ciaccia, president of consulting firm 3 Axis Advisors and founder/CEO of non-profit 46brooklyn Research, joins host Dan Karnuta for a discussion about U.S. drug pricing. The model is opaque because it runs on inflated list prices and hidden discounts created by government policy and industry incentives. Instead of competing on price, drug companies raise prices and offer rebates through intermediaries like pharmacy benefit managers (PBMs), who control which drugs are covered. This system weakens normal market forces and concentrates power in the middle of the supply chain. Karnuta is an associate professor in the Naveen Jindal School of Management's Organizations, Strategy and International Management Area as well as director of its Professional Program in Healthcare Management.

his episode looks at where Q10 fits in the broader quality landscape, including its roots in ISO 9001, ISO 9004, and ISO 13485, while making the key distinction that Q10 is not a certifiable ISO-style standard. Instead, Q10 is designed to augment regional GMPs and provide a lifecycle model for managing pharmaceutical quality.Using the Annex 2 PQS diagram, Subhi walks through how Q10 applies across pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation. The episode discusses phase-appropriate GMP expectations, why Q10 does not replace GMP, and how management responsibility spans the full lifecycle, including outsourced activities and purchased materials.The episode also covers the four core PQS elements: process performance and product quality monitoring, CAPA, change management, and management review. These elements are presented as operational loops that help maintain control and drive improvement. Subhi also highlights the two key enablers of the model: knowledge management, connected to ICH Q8, and quality risk management, connected to ICH Q9.The episode closes with Section 4 of Q10, which focuses on continual improvement of the PQS itself, including management review inputs, external changes, resourcing, documentation, and communication.00:00 Welcome and Series Setup00:14 Why ICH Q10 Matters01:21 Lifecycle and Phase-Appropriate GMP02:23 GMP Foundation and the PQS Model02:58 Management Responsibility03:31 Core PQS Elements04:26 Enablers: Knowledge Management and QRM04:40 Guideline Walkthrough: Sections 1 to 306:37 Continual Improvement of the PQS07:45 Wrap Up and Next EpisodeSubhi Saadeh is the Founder and Principal at Let's Combinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, and regulatory expectations across drug and device domains. He is a consultant, auditor, trainer, and speaker with experience across companies including Pfizer, Gilead, and Baxter, supporting the development and launch of combination products across vaccines, biologics, and generics, including leading and supporting combination product transformations across large organizations.

What if one shot could reverse a meth overdose? In this episode of Sounds of Science, we explore CS1103 - Clear Scientific's breakthrough therapy with FDA Fast Track status that works like Pac-Man to clear toxins fast. Could this change emergency medicine forever? Tune in to find out. Clear Scientific: Combatting Drug Overdose from Methamphetamine, Fentanyl, and Polydrug | Charles River Podcast IND-Enabling Studies | Charles River Small Molecule Drug Development | Charles River Safety Assessment | Charles River 

Many pharmaceutical giants use monkeys to test drugs and vaccines. But since China banned the export of primates in 2020, prices have skyrocketed, fuelilng an international black market. At the heart of this illegal trafficking are Cambodia, Thailand and Laos. FRANCE 24's Justin McCurry, Théo Collet, Antoine Morel and Cyrille Charpentier report. 

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Pharmaceutical launches are among the most complex, high-stakes endeavors in all of healthcare, and the difference between winning and losing often comes down to whether the right intelligence reaches the right people at the right moment.Jason Smith, CTO of AI and Analytics at Within3, has spent his career solving exactly that problem.A three-time co-founder whose companies have raised over $100 million in venture capital, Jason built rMark Bio from scratch before its acquisition by Within3, where his AI platform now powers launch decisions for all of the top 20 pharmaceutical companies.Join us as Jason discusses how Within3's Launch Intelligence platform unifies field insights, social signals, EHR data, and stakeholder engagement into one integrated layer, empowering pharma teams to move with clarity and confidence. Let's go!Episode Highlights:Jason sold his house, packed his dog in a U-Haul, and drove from Seattle to Chicago to launch rMark Bio in 2015.Within3 analyzes over 10 billion data points, filtered into hyper-focused disease community landscapes for pharmaceutical decision-makers.Life sciences AI differs from general models because context matters: how an MSL communicates is entirely different from a general user's query.Social listening gives pharma companies real-time aggregate patient and HCP sentiment, replacing slow, one-to-one relationship-based feedback loops.Jason is an 18-year cancer survivor and American Cancer Society advisor, making him personally invested in faster, better therapeutics for patients.About our Guest:Jason Smith is CTO of AI & Analytics at Within3, where he leads the team behind the company's most advanced AI capabilities serving life sciences organizations. Jason is a three-time co-founder who built Cryptocybernetics, GrayArea, and rMark Bio from inception to successful exit. He was later brought in as CEO of xSides to lead its sale. Over his career, his companies have raised more than $100 million in venture and strategic capital. In addition to Within3, Jason is a Venture Fellow at MATTER, Advisor to Capita3, and a recognized thought leader in AI and Healthcare with publications and speaking engagements at HIMSS, Reuters, and leading healthcare and pharmaceutical conferences.Links Supporting This Episode: Within3 Website: CLICK HEREJason Smith LinkedIn page: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE

As the 2026 midterm elections approach, healthcare leaders are asking whether this is just another policy cycle or a more pivotal moment in an increasingly complex and fragmented landscape. In this episode of PwC's Next in Health, Glenn Hunzinger speaks with Kelly Griffin and Philip Sclafani about how shifting policy dynamics, persistent cost pressures, and rapid industry transformation are reshaping strategy across the healthcare ecosystem. Discussion highlights:Why the 2026 midterms are less about sweeping reform and more about signaling the direction of the operating environmentHow affordability, transparency, and increased state-level action are shaping policy and driving industry changeWhy healthcare costs continue to rise and why traditional levers may not be enough to bend the cost curveHow pharma, payers, and providers are adapting business models amid regulatory pressure and evolving market dynamicsThe growing role of AI, partnerships, and ecosystem convergence in accelerating transformationWhat healthcare leaders should prioritize, from policy intelligence and scenario planning to operating effectively in a more fragmented environment  Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Kelly Griffin, Director, Health Policy and Intelligence Institute, PwC Philip Sclafani, Principal, Pharmaceutical and Life Sciences, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Listen in as our expert panel covers the latest evidence on using menopausal hormone therapy and nonhormonal options for treatment of vasomotor symptoms (hot flashes, etc). You'll also hear experts discuss treatments for genitourinary symptoms (vaginal dryness, etc) as well as low libido and brain fog.Special guests:Veronica Vernon, PharmD, BCPS, BCACP, MSCP, FAPhA Associate Professor, Chair of Pharmacy PracticeButler UniversitySarah M. Westberg, PharmD, FCCP, BCPSAssociate Dean for Professional Affairs Professor, College of PharmacyUniversity of MinnesotaYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Andrea Darby-Stewart, MDAssociate Director, Honor Health Family Medicine Residency ProgramClinical Professor of Family, Community & Occupational MedicineThe University of Arizona College of Medicine – PhoenixCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in March 2026.

After over two decades relying solely on medication, reaching a point where insulin was recommended, Shantanu Srivastava recognized a critical gap across multiple healthcare systems which all treated symptoms rather than addressing underlying causes of chronic disease. His observation revealed that medication-centric approaches in India clash with cultural resistance to lifestyle changes, while the UK's public healthcare, though excellent at prevention, lacks proactive support for those willing to go beyond standard care. This gap between what people need and what systems provide became his catalyst for reimagining healthcare entirely. Rather than judging reactions—Shantanu creates the foundation for trust and effective collaboration across cultures. He advocates for a philosophy where leaders maintain their North Star during crises, solve problems through doing the right things faster rather than doing wrong things harder, and make conscious choices to preserve values over short-term gains. His practical example of selectively declining consultation inquiries she cannot genuinely help demonstrates how this integrity translates into business decisions that build trustworthiness and long-term sustainability, even when financial pressure tempts compromise. Explore Health Verse through their website at healthverse.uk to access credible self-learning resources and connect with genuine health practitioners. Whether you're managing a chronic condition, building a startup, or simply seeking to prioritize self-care in an increasingly pressured world, Shantanu Srivastava's emphasis on authentic community, integrated knowledge, and doing the right things faster provides a foundation for meaningful transformation. For the accessible version of the podcast, go to our Ziotag gallery.We're happy you're here! Like the pod?Support the podcast and receive discounts from our sponsors: https://yourbrandamplified.codeadx.me/Leave a rating and review on your favorite platformFollow @yourbrandamplified on the socialsTalk to my digital avatar Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This episode continues the ICH Quality Series with an overview of ICH Q8 (Pharmaceutical Development), focusing on what it is, how it's structured, and how to think about it in practice.ICH Q8 defines the suggested contents for CTD Section 3.2.P.2 and aims to harmonize how pharmaceutical development is presented in regulatory submissions. It primarily applies to drug product development and later-stage submissions, where a full understanding of the product and process is expected.The guideline is structured in three parts: the core sections, which outline development elements such as formulation, manufacturing, and container closure; the annexes, which introduce key Quality by Design concepts including QTPP, CQAs, risk assessment, design space, and control strategy; and a final section that explains how this information is organized across the CTD.The episode walks through the relationship between TPP and QTPP, defines critical quality attributes, explains how design space is established through prior knowledge, risk assessment, and experimental work such as design of experiments, and outlines how a control strategy is built across materials, process controls, monitoring, and testing.High Level QBD(4 min): https://www.youtube.com/watch?v=orlPpfQvb5kQBD vs. Design Controls: https://www.youtube.com/watch?v=W_LSD0kKQ3400:00 Introduction to ICH Q800:42 Related QbD Videos01:12 Structure of ICH Q802:28 Objective and Scope04:49 Annexes and QbD Concepts05:20 Quality Target Product Profile06:33 Critical Quality Attributes07:09 Design Space and DoE09:17 Control Strategy10:06 Submission and Wrap-UpSubhi Saadeh is the Founder and Principal at Let's ComBinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, and regulatory expectations across drug and device domains.A consultant, auditor, and trainer, Subhi has worked across companies including Baxter, Pfizer, and Gilead, supporting the development, manufacturing, and launch of medical devices and combination products for vaccines, generics, and biologics.

We are joined by retiring CEO Jim Foster to discuss his 50 year career at Charles River. Through his decades in the industry, Foster has seen it all - from the shift toward new approach methodologies, through mergers and sales and public offerings, to shaping the future of Charles River's culture. Listen now to hear how it all started, how we got here, and where we are heading in the future.

The tape worm is benign. Intro Music: Celtic Frost- Vanity Submit music to demolistenpodcast@gmail.com. Become a patron at https://www.patreon.com/demolistenpodcast. Leave us a message at (260)222-8341 Queue: Subjects, humanhostbody, The High Cost Of Playing God, Obelisk, Sicko, Dorkwind, Ditch, Spiritual Law, Brainwash Victims, Deprivation https://youthattack.bandcamp.com/album/subjects https://humanhostbody.bandcamp.com/album/brez-izhoda-brez-upanja https://thehighcostofplayinggod.bandcamp.com/album/bastard https://obeliskmtl.bandcamp.com/album/call-to-oblivion https://sicko-ontherun.bandcamp.com/album/fever-running-wild https://dorkwind.bandcamp.com/album/stressed-out-stressed-out  

This episode dives deep into the scientific, medical, and societal aspects of the COVID-19 pandemic. Prof Robert Clancy reflects on how long-established pandemic plans were abandoned, why certain treatments were dismissed, and how messaging shaped public perception. The discussion covers vaccine technology, natural immunity, the role of pharmaceutical influence, and the gaps in medical education that contributed to widespread confusion. It’s a candid exploration of what went right, what went wrong, and what must change moving forward. ◉

In this episode of Sounds of Science, Lauren and Matt Noonan share their powerful journey following their daughter Jane's diagnosis with Mowat-Wilson Syndrome. From unexpected medical challenges to finding community and launching their own nonprofit, the OURS Foundation, they discuss how advocacy, collaboration, and emerging research are shaping new hope for families living with rare diseases. Charles River | ASO Development Charles River | ASO Screening Services Charles River | Rare Disease Charles River | Rare Disease Research for Drug Development Mowat Wilson Foundation

Full Show Notes: bengreenfieldlife.com/ways2well In this episode, I sit down with Brigham Buhler at Ways2Well in Austin, Texas, exposing the "sick care" maze, including insurance company middlemen, skyrocketing drug prices, and the rebate system nobody talks about. This is what optimizing your health actually looks like: not managing disease, not waiting for a diagnosis, but getting inside the lab and taking control. Brigham Buhler is a healthcare entrepreneur, founder of Ways2Well, and owner of ReviveRX. He spent years inside the systems he now fights against, working across pharmaceutical sales and sports medicine before building a cash-pay alternative to the insurance model. Ways2Well is a clinician-led health company built around continuous, personalized care. They combine advanced diagnostics, expert interpretation, individualized treatment plans, and regenerative therapies to help patients understand what's actually happening in their bodies, rather than solely treating symptoms. Ready to take control of your health with personalized care and treatments that the standard system won't offer? You can use code BOUNDLESS for 10% off a Ways2Well Annual Membership. Episode Sponsors: TruDiagnostic: TruDiagnostic is an advanced at-home health test that uses epigenetic analysis to measure over a million biomarkers, giving you personalized, data-driven insights into your aging, energy, and overall health so you can stop guessing and start optimizing with a clear plan. Visit TruDiagnostic.com and use code BEN for 10% off. BASED Bodyworks: BASED Bodyworks is a clean, plant-based men's grooming brand offering simple, high-performance essentials from shampoo and skincare to styling, formulated without harsh sulfates or hormone-disrupting chemicals, so you can look and feel your best without compromising your health. Visit basedbodyworks.com and use code BOUNDLESSLIFE for 20% off. ULTRA: ULTRA is a clean, nicotine-free, and caffeine-free pouch designed to deliver smooth, sustained energy and focus using clinically backed nootropics and adaptogens without the jitters, crashes, or sleep disruption. With flavors like their new Blue Razz, it’s a simple, effective way to stay sharp throughout the day. Visit takeultra.com and use code BENGREENFIELD for 15% off. Our Place: Upgrade your kitchen and say goodbye to forever chemicals for good. Right now, they’re having their biggest sale of the season, with up to 40% off site-wide through April 12th. Head to fromourplace.com/BEN to see why more than a million people have already made the switch to their clean, thoughtfully designed cookware. Sunlighten: Sunlighten's patented infrared sauna technology delivers the highest quality near-, mid-, and far-infrared wavelengths to reduce inflammation, boost mitochondrial function, enhance detox pathways, and optimize recovery, backed by 25+ years of clinically proven, non-toxic innovation. Save up to $1,600 at get.sunlighten.com/ben with code BEN.See omnystudio.com/listener for privacy information.

The FDA's approval of a higher-dose Wegovy marks Novo Nordisk's aggressive push to reclaim market share in the exploding weight loss drug sector. Pharmaceutical investors are watching closely as competition intensifies in what could become a trillion-dollar market.Today's Stocks & Topics: Berkshire Hathaway Inc. (BRK.B), Market Wrap, Snap Inc. (SNAP), Caterpillar Inc. (CAT), Weight Loss Drug Stocks: Biotech Breakthrough or Market Bubble?, CDW Corporation (CDW), Petrochemical Companies, Lumen Technologies, Inc. (LUMN), Mortgage Rates, Mueller Industries, Inc. (MLI), Fertilizer Market.Introducing our Third Annual InvestTalk Market Madness! Join the mayhem before May 18th at 11:59 pm PST for the chance to win $1,500! Fill out your bracket below: https://kppfinancial.com/investtalk-madnessOur Sponsors:* Check out Anthropic: https://claude.ai/invest* Check out Pebl: https://hipebl.ai* Check out Progressive: https://progressive.com* Check out Quince: https://quince.com/INVESTAdvertising Inquiries: https://redcircle.com/brands

Andrea Stricker discusses reports that the Iranian regime used illicit chemicals and pharmaceutical-based agents to debilitate protesters during recent, highly lethal national unrest. 9.1610

Gregory Zuckerman details Gail Smith's insect-based vaccine technology at Novavax and discusses how major pharmaceutical giants like Merck initially hesitated to join the pandemic race. 4